Detect altered DNA

With ~90% sensitivity and ~99% negative predictive value at detecting Barrett's esophagus and esophageal adenocarcinoma, the EsoGuard test allows detection of these conditions in a simple office-based procedure without endoscopy.

1,2,3

~99%
negative predictive value
at detecting Barrett's esophagus and
esophageal adenocarcinoma

1,2,3

~90%
sensitivity
at detecting BE, with and without dysplasia, as
well as esophageal adenocarcinoma

1,2,3

EsoGuard analyzes methylation at

31 sites on 2 genes

Read the Study

A test that goes down easy

Barrett’s esophagus is a premalignant condition of the distal esophagus that increases the risk of esophageal cancer. Unfortunately, screening for Barrett’s esophagus currently requires endoscopy, an invasive and expensive procedure, and thus, it is not routinely performed. Moinova et al. have now demonstrated a simplified approach to screening by identifying a pair of DNA methylation markers that correlate with the presence of Barrett’s esophagus. The authors also invented a swallowable balloon-based device that can capture DNA samples for methylation analysis and found that it is well tolerated in patients and provides >90% sensitivity and specificity compared to endoscopy, suggesting its potential as a screening method.

Science Translational Medicine 17 Jan 2018:
Vol. 10, Issue 424, eaao5848
DOI: 10.1126/scitranslmed.aao5848

How it works

Distal esophageal cells are sampled in a simple office-based procedure, shipped in preservative with the provided mailer, and processed at our laboratory. Results are typically available within 3 weeks.

Cell Collection

Distal esophageal cells are sampled in a simple office-based procedure and sent to our laboratory.

Test

The EsoGuard Esophageal DNA Test assesses signature epigenetic changes indicative of BE and EAC using advanced molecular diagnostic techniques.

Results

The physician receives a report with a positive or negative result indicating whether or not epigenetic changes consistent with BE/EAC were detected.

Meet the team behind the test

Researchers, Physicians, Scientists, Innovators, Educators

EsoGuard was developed through the National Cancer Institute and arose from a collaboration among Case Western Reserve University faculty, including renowned cancer geneticists, a passionate gastroenterologist, and a dedicated pathologist.

SANDY MARKOWITZ, MD

Physician, Department of Hematology and Oncology

Ingalls Professor of Cancer Genetics, Department of Medicine, School of Medicine

Professor, Department of Genetics and Genome Sciences, School of Medicine

Professor, Department of Molecular Biology and Microbiology, School of Medicine

Principal Investigator, Case GI SPORE, Case Comprehensive Cancer Center

Co-Leader, GI Cancer Genetics

Program, Case Comprehensive Cancer Center

Case Western Reserve University

University Hospitals Cleveland Medical Center

AMITABH CHAK, MD

Physician, Department of Gastroenterology, University Hospitals Cleveland Medical Center

Professor, Department of Medicine, School of Medicine

Member, Cancer Genomics and Epigenomics Program, Case Comprehensive Cancer Center

Case Western Reserve University

University Hospitals Cleveland
Medical Center

JOE WILLIS, MD

Vice Chairman of Pathology, Clinical Affairs, Laboratory Director, University Hospitals Cleveland Medical Center

Professor, Department of Pathology, School of Medicine

Member, Cancer Genomics and Epigenomics Program, Case Comprehensive Cancer Center

Case Western Reserve University

University Hospitals Cleveland
Medical Center

Ready to start screening with EsoGuard?

Incorporating EsoGuard in your practice is easy. Reach out today and we'll get you started.

Request a Representative

REFERENCES:

1. Moinova, Helen R et al. “Multicenter, prospective trial of non-endoscopic biomarker-driven detection of f Barrett’s Esophagus and Esophageal Adenocarcinoma.” The American Journal of Gastroenterology (2024): 10-14309.

2. Greer, Katarina B et al. “Non-endoscopic screening for Barrett’s Esophagus and Esophageal Adenocarcinoma in at risk veterans.” medRxiv (2024): 2024-03 [Preprint.

3. Shaheen, N., et al., Use of the EsoGuard® Molecular Biomarker Test in Non-Endoscopic Detection of Barrett's Esophagus among High-Risk Individuals in a Screening Population. medRxiv, 2024: p. 2024.06.24.24309401.

Detect altered DNA

With ~90% sensitivity and ~99% negative predictive value at detecting Barrett's esophagus and esophageal adenocarcinoma, the EsoGuard test allows detection of these conditions in a simple office-based procedure without endoscopy.

1,2,3

~99% negative predictive value at detecting Barrett's esophagus and esophageal adenocarcinoma

~90% sensitivity at detecting BE, with and without dysplasia, as well as esophageal adenocarcinoma

A test that goes down easy

​

Distal esophageal cells are sampled in a simple office-based procedure, shipped in preservative with the provided mailer, and processed at our laboratory. Results are typically available within 3 weeks.

Meet the team behind the test

Researchers, Physicians, Scientists, Innovators, Educators

EsoGuard was developed through the National Cancer Institute and arose from a collaboration among Case Western Reserve University faculty, including renowned cancer geneticists, a passionate gastroenterologist, and a dedicated pathologist.

SANDY MARKOWITZ, MD

AMITABH CHAK, MD

JOE WILLIS, MD

Ready to start screening with EsoGuard?

~99%
negative predictive value
at detecting Barrett's esophagus and
esophageal adenocarcinoma

~90%
sensitivity
at detecting BE, with and without dysplasia, as
well as esophageal adenocarcinoma